Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Business Wire

04 Aug 2026, 05:39 UTC · 1h ago

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

What the story claims

1 claim · each scored for market impact

What matters in this story

1
Dr. Reddy's Laboratories has launched a generic equivalent of Bridion (Sugammadex Injection) in the United States. — Entering the US market with a generic version of a branded drug typically increases revenue streams for the generic manufacturer while eroding the moat of the original patent holder.
+0.40

Which stocks this story touches

How each ticker is affected

RDY+0.60
The company is expanding its product portfolio in the U.S. market by launching a generic equivalent of Sugammadex.

Connected tickers

RDY→BRIDION

6 related stories

Zacks Investment Research
12h ago
Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?
- healthcare
- pharma
Read

Dr. Reddy's Announces the… — RDY +0.60 | NewsImpactScreener

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

What matters in this story

How each ticker is affected

Connected tickers

Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

What matters in this story

How each ticker is affected

Connected tickers

Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Johnson & Johnson (JNJ) Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System Transcript

Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?

Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again

Inspire Medical Systems, Inc. (INSP) Q2 2026 Earnings Call Transcript

UK's Smith+Nephew cuts annual revenue expectations

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

What matters in this story

How each ticker is affected

Connected tickers

Next reads from the same story arc

Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

What matters in this story

How each ticker is affected

Connected tickers

Next reads from the same story arc

Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Johnson & Johnson (JNJ) Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System Transcript

Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?

Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again

Inspire Medical Systems, Inc. (INSP) Q2 2026 Earnings Call Transcript

UK's Smith+Nephew cuts annual revenue expectations